

## Doç.Dr. LEYLA OZER

### Kişisel Bilgiler

İş Telefonu: [+90 212 404 4553](tel:+902124044553)  
Fax Telefonu: [+90 212 404 4444](tel:+902124044444)  
E-posta: [leyla.ozer@acibadem.edu.tr](mailto:leyla.ozer@acibadem.edu.tr)  
Web: <https://avesis.acibadem.edu.tr/11111>

### Eğitim Bilgileri

Tıpta Yandal Uzmanlık, İstanbul Üniversitesi, Onkoloji Enstitüsü, Klinik Onkoloji Ana Bilim Dalı, Türkiye 2009 - 2013  
Tıpta Uzmanlık, İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye 2002 - 2008  
Lisans, Türkiye 1996 - 2002

### Araştırma Alanları

Tıp, Sağlık Bilimleri

### Akademik Unvanlar / Görevler

Doç.Dr., Acibadem Mehmet Ali Aydınlar Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2015 - Devam Ediyor

### Akademik İdari Deneyim

İÇ HASTALIKLARI STAJ KOORDİNATÖR YARDIMCILIĞI, Acibadem Mehmet Ali Aydınlar Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2018 - Devam Ediyor  
Bölüm Başkanı, Fırat Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, 2014 - 2015

### Verdiği Dersler

SIDE EFFECTS OF CHEMOTHERAPY, Lisans, 2019 - 2020

### Jüri Üyelikleri

Tez Savunma (Doktora), Tez Savunma (Doktora), İstanbul Üniversitesi, Mayıs, 2019

### SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

- Tailored total neoadjuvant therapy for locally advanced rectal cancer: One size may not fit for all!**  
Ozer L., Yıldız İ., Bayoğlu V., Bozkurt M., Esen E., Remzi F. H. , Gogenur I., Aytaç E.  
COLORECTAL DISEASE, 2021 (SCI İndekslerine Giren Dergi)
- The expression levels of miRNA-15a and miRNA-16-1 in circulating tumor cells of patients with**

### **diffuse large B-cell lymphoma**

Tuncer S. B. , Akdeniz D., Celik B., Kilic S., Sukruoglu O., Avsar M., Ozer L., Ekenel M., Ozel S., Yazici H.  
Molecular Biology Reports, cilt.46, sa.1, ss.975-980, 2019 (SCI İndekslerine Giren Dergi)

- III. **Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy.**  
Yildiz İ., Bilici A., Karadurmus N., Ozer L., Tural D., Kaplan M. A. , Akman T., Bayoglu I., UYSAL M., Yildiz Y., et al.  
Tumori, cilt.104, sa.6, ss.444-450, 2018 (SCI Expanded İndekslerine Giren Dergi)
- IV. **Clinical significance of serum interleukin-17 levels in colorectal cancer patients**  
Karabulut S., Afsar C. U. , Karabulut M., Kilic L., Alis H., Kones O., Bilgin E., Aykan N. F.  
JOURNAL OF BUON, cilt.21, sa.5, ss.1137-1145, 2016 (SCI İndekslerine Giren Dergi)
- V. **Current adjuvant treatment modalities for gastric cancer: From history to the future**  
Kilic L., Ordu C., Yildiz İ., Sen F., Keskin S., Ciftci R., Pilanci K. N.  
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, cilt.8, sa.5, ss.439-449, 2016 (SCI İndekslerine Giren Dergi)
- VI. **Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma**  
Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U. , Karanlik H., Kurul S., Vatanserver S., Oral E. N. , et al.  
JOURNAL OF DERMATOLOGICAL TREATMENT, cilt.27, sa.3, ss.275-277, 2016 (SCI İndekslerine Giren Dergi)
- VII. **Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer**  
Tas F., Yildiz İ., Kilic L., Ciftci R., Keskin S., Sen F.  
AMERICAN JOURNAL OF THERAPEUTICS, cilt.23, sa.3, 2016 (SCI İndekslerine Giren Dergi)
- VIII. **Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma**  
Sen F., Yildiz İ., Odabas H., Tambas M., Kilic L., Karadeniz A., Altun M., Ekenel M., Serilmez M., Duranyildiz D., et al.  
TUMOR BIOLOGY, cilt.36, sa.2, ss.1039-1044, 2015 (SCI İndekslerine Giren Dergi)
- IX. **D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients**  
Kilic L., Yildiz İ., Sen F. K. , Erdem M. G. , Serilmez M., Keskin S., Ciftci R., Karabulut S., Ordu C., Duranyildiz D., et al.  
CANCER BIOMARKERS, cilt.15, sa.4, ss.405-411, 2015 (SCI İndekslerine Giren Dergi)
- X. **Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.**  
Yildiz İ., Varol U., Sen F., Kilic L.  
Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, cilt.14, sa.7, ss.654-6, 2014 (SCI İndekslerine Giren Dergi)
- XI. **The behavior of Turkish cancer patients in fasting during the holy month of Ramadan.**  
Tas F., Karabulut S., Ciftci R., Yildiz İ., Keskin S., Kilic L., Disci R.  
Japanese journal of clinical oncology, cilt.44, sa.8, ss.705-10, 2014 (SCI İndekslerine Giren Dergi)
- XII. **High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer.**  
Ciftci R., Tas F., Yasasever C. T. , Aksit E., Karabulut S., Sen F., Keskin S., Kilic L., Yildiz İ., Bozbey H. U. , et al.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, cilt.35, sa.7, ss.6941-8, 2014 (SCI İndekslerine Giren Dergi)
- XIII. **Coagulation tests show significant differences in patients with breast cancer.**  
Tas F., Kilic L., Duranyildiz D.  
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, cilt.35, ss.5985-92, 2014 (SCI İndekslerine Giren Dergi)
- XIV. **Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up.**  
Elitok A., Oz F., Cizgici A., Kilic L., Ciftci R., Sen F., Bugra Z., Mercanoglu F., Oncul A., Oflaz H.  
Cardiology journal, cilt.21, ss.509-15, 2014 (SCI İndekslerine Giren Dergi)
- XV. **Clinical significance of coagulation assays in metastatic pancreatic adenocarcinoma.**  
Tas F., Karabulut S., Bilgin E., Kilic L., Ciftci R., Duranyildiz D.  
Journal of gastrointestinal cancer, cilt.44, ss.404-9, 2013 (SCI Expanded İndekslerine Giren Dergi)

- XVI. **Age is a prognostic factor affecting survival in lung cancer patients.**  
Tas F., Ciftci R., Kilic L., Karabulut S.  
Oncology letters, cilt.6, ss.1507-1513, 2013 (SCI İndekslerine Giren Dergi)
- XVII. **Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.**  
Tas F., Sen F., Odabas H., Kilic L., Keskin S., Yildiz İ.  
International journal of clinical oncology, cilt.18, sa.5, ss.839-46, 2013 (SCI İndekslerine Giren Dergi)
- XVIII. **Clinical and prognostic significance of coagulation assays in gastric cancer.**  
Tas F., Ciftci R., Kilic L., Serilmez M., Karabulut S., Duranyildiz D.  
Journal of gastrointestinal cancer, cilt.44, ss.285-92, 2013 (SCI Expanded İndekslerine Giren Dergi)
- XIX. **Serum M65 as a biomarker for metastatic renal cell carcinoma.**  
Yildiz İ., Sen F., Kilic L., Keskin S., Duranyildiz D., Bilgin E., Disci R., Ekenel M., Darendeliler E., Bavbek S., et al.  
Clinical genitourinary cancer, cilt.11, sa.3, ss.290-6, 2013 (SCI İndekslerine Giren Dergi)
- XX. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer**  
Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, cilt.72, sa.2, ss.437-444, 2013 (SCI İndekslerine Giren Dergi)
- XXI. **Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naïve non-small cell lung cancer.**  
Keskin S., Tas F., Ekenel M., Kilic L., Sen F., Yildiz İ., Karabulut S., Ciftci R., Vatansever S.  
Tumori, cilt.99, sa.4, ss.463-8, 2013 (SCI İndekslerine Giren Dergi)
- XXII. **Clinical and prognostic significance of coagulation assays in lung cancer.**  
Tas F., Kilic L., Serilmez M., Keskin S., Sen F., Duranyildiz D.  
Respiratory medicine, cilt.107, ss.451-7, 2013 (SCI İndekslerine Giren Dergi)
- XXIII. **Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.**  
Aydiner A., Kilic L., Yildiz İ., Keskin S., Sen F., Kucucuk S., Karanlik H., Muslumanoğlu M., Igci A.  
Medical oncology (Northwood, London, England), cilt.30, sa.1, ss.354, 2013 (SCI İndekslerine Giren Dergi)
- XXIV. **Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer.**  
Tas F., Kilic L., Bilgin E., Keskin S., Sen F., Ciftci R., Yildiz İ., Yasasever V.  
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, cilt.23, sa.2, ss.276-81, 2013 (SCI İndekslerine Giren Dergi)
- XXV. **Does beta-blocker therapy improve the survival of patients with metastatic non-small cell lung cancer?**  
Aydiner A., Ciftci R., Karabulut S., Kilic L.  
Asian Pacific journal of cancer prevention : APJCP, cilt.14, ss.6109-14, 2013 (SCI İndekslerine Giren Dergi)
- XXVI. **Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.**  
Aykan N. F., Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., Karabulut S., Sakar B., Disci R.  
Medical oncology (Northwood, London, England), cilt.30, sa.3, ss.679, 2013 (SCI İndekslerine Giren Dergi)
- XXVII. **Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?**  
Kilic L., Ordu C., Ekenel M., Yildiz İ., Keskin S., Sen F., Gural Z., Asoglu O., Kizir A., Aykan F.  
Medical oncology (Northwood, London, England), cilt.30, sa.3, ss.660, 2013 (SCI İndekslerine Giren Dergi)
- XXVIII. **Clinical and prognostic significance of coagulation assays in melanoma.**  
Tas F., Ciftci R., Kilic L., Bilgin E., Keskin S., Sen F., Yildiz İ., Yasasever V.  
Melanoma research, cilt.22, sa.5, ss.368-75, 2012 (SCI İndekslerine Giren Dergi)
- XXIX. **The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.**  
Sanli Y., Kuyumcu S., Ozkan Z., Kilic L., Balik E., Turkmen C., Has D., Isik G., Asoglu O., Kapran Y., et al.  
Annals of nuclear medicine, cilt.26, ss.551-8, 2012 (SCI İndekslerine Giren Dergi)
- XXX. **Noncutaneous Melanoma Have Distinct Features from Each Other and Cutaneous Melanoma**

Tas F., Keskin S., Karadeniz A., Dagoglu N., Sen F., Kilic L., Yildiz İ.

ONCOLOGY, cilt.81, ss.353-358, 2011 (SCI İndekslerine Giren Dergi)

**XXXI. Optic disc and choroidal metastasis from sporadic medullary thyroid carcinoma: case report and review of the literature.**

Yildiz İ., Sen F., Tuncer S., Kilic L., Basaran M., Bavbek S.

Onkologie, cilt.34, sa.11, ss.630-3, 2011 (SCI İndekslerine Giren Dergi)

**XXXII. The Properties of Vitamin B12 Deficiency in the Patients of an Outpatient Clinic**

Erden S., Sakar S., Koc Z., Sen F., Cakir H., Gelincik A., Kilic L., Ozdener L.

TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, cilt.30, sa.6, ss.1845-1851, 2010 (SCI İndekslerine Giren Dergi)

## **Diğer Dergilerde Yayınlanan Makaleler**

**I. The Youngest Patient with Metastatic Leiomyosarcoma of the Pancreas.**

Saka D., Şişman G., Özer L., Şahin D., Ceyhan G.

Journal of gastrointestinal cancer, cilt.51, ss.722-723, 2020 (Diğer Kurumların Hakemli Dergileri)

**II. Neoadjuvant sequential chemoradiotherapy versus radiotherapy alone for treatment of high-risk extremity soft tissue sarcoma: a single-institution experience.**

Kılıç L., Ekenel M., Karabulut S., Ağaoğlu F., Darendeliler E.

Contemporary oncology (Poznan, Poland), cilt.21, ss.60-65, 2017 (ESCI İndekslerine Giren Dergi)

**III. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.**

Karabulut S., Afsar Ç., Karabulut M., Alış H., Kılıç L., Çikot M., Yasasever C., Aykan N.

Journal of gastrointestinal cancer, cilt.47, ss.47-54, 2016 (ESCI İndekslerine Giren Dergi)

**IV. The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience.**

Eralp Y., Kılıç L., Alço G., Başaran G., Doğan M., Dinçol D., Demirci S., İçli F., Onur H., Saip P., et al.

The journal of breast health, cilt.10, ss.209-215, 2014 (ESCI İndekslerine Giren Dergi)

**V. Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.**

Yildiz İ., Sen F., Kilic L., Ciftci R., BAŞARAN M.

Korean journal of urology, cilt.55, sa.1, ss.74-6, 2014 (ESCI İndekslerine Giren Dergi)

**VI. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival.**

Tas F., Sen F., Keskin S., Kilic L., Yildiz İ.

Molecular and clinical oncology, cilt.1, ss.788-792, 2013 (ESCI İndekslerine Giren Dergi)

## **Kitap & Kitap Bölümleri**

**I. Hematopoetik Tedaviler**

Ozer L.

ONKOLOJİ HEMŞİRELİĞİ, gülbeyaz can, Editör, Nobel Yayın Dağıtım, İstanbul, ss.655-666, 2020

**II. ADJUVANT CHEMOTHERAPY FOR HER2-NEGATIVE EARLY STAGE BREAST CANCER**

Ozer L.

BREAST CANCER - A GUIDE TO CLINICAL PRACTICE , ADNAN AYDINER, ATILLA SORAN, ABDULLAH IGCI, Editör, Springer, London/Berlin , Geneve, ss.357-383, 2019

## **Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar**

**I. Factors affecting progression free survival in non-HIV related classical Kaposi sarcoma.**

Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U. , Karanlik H., Kurul S., Vatansever S., Saip P., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting  
and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02  
Haziran 2015, cilt.33

**II. OUTCOME OF BRAIN METASTASES FROM COLORECTAL CANCER; A SINGLE INSTITUTE EXPERIENCE**

Ekenel M., Kilic L., Aykan F. N.

35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, İtalya, 8 - 12 Ekim 2010, cilt.21, ss.224

## **Bilimsel Hakemlikler**

journal of oncological Sciences , Diğer Dergiler, Mayıs 2020

## **Atıflar**

Toplam Atıf Sayısı (WOS):410

h-indeksi (WOS):12